---
title: Hepatology
description: Resources and insights tagged ta hepatology from Pedestal Health.
category: Tag
canonical_url: https://www.pedestalhealth.com/categories/hepatology/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: hepatology
id: 2gat8p14f5HcXdGRpNqcNk
contentType: tag
---

# Hepatology

Resources and insights tagged ta hepatology from Pedestal Health.

- [Leveraging AI-driven natural language processing to enhance symptom capture in primary biliary Cholangitis (PBC) and primary Sclerosing Cholangitis (PSC)](https://www.pedestalhealth.com/resources/publications/poster-presentation/ai-nlp-symptom-capture-pbc-psc/)
- [Analysis of Structured and Unstructured Data From a Large Electronic Health Record System Identifies Frequent Pruritus and Fatigue in Patients With PSC](https://www.pedestalhealth.com/resources/publications/poster-presentation/structured-unstructured-data-ehr-pruritus-fatigue-psc/)
- [Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease](https://www.pedestalhealth.com/resources/publications/poster-presentation/changes-in-the-fibrosis-4-fib-4-score-accurately-reflects/)
- [Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort](https://www.pedestalhealth.com/resources/publications/poster-presentation/clinical-characteristics-of-patients-with-presumed-masld/)
- [The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/the-magnitude-of-polypharmacy-and-role-of-disease-severity/)
- [Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/cardiovascular-risk-assessment-tools-are-insufficient-for/)
- [DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/daa-pass-a-prospective-evaluation-of-hcc-recurrence-after/)
- [Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions](https://www.pedestalhealth.com/resources/publications/poster-presentation/relationship-between-non-invasive-tests-clinical-outcomes/)
- [Type 2 Diabetes and Obesity are The Main Metabolic Risk Factors for The Development of Cirrhosis in People with Metabolic Dysfunction Associated Steatohepatitis](https://www.pedestalhealth.com/resources/publications/poster-presentation/type-2-diabetes-and-obesity-are-the-main-metabolic-risk/)
- [Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)](https://www.pedestalhealth.com/resources/publications/poster-presentation/real-world-treatment-patterns-among-us-adults-with/)
- [Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry](https://www.pedestalhealth.com/resources/publications/poster-presentation/real-world-treatment-patterns-and-outcomes-for/)
- [Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality](https://www.pedestalhealth.com/resources/publications/oral-presentation/use-of-glucagon-like-peptide-1-receptor-agonists-in/)
- [Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status](https://www.pedestalhealth.com/resources/publications/poster-presentation/stability-of-the-nash-check-patient-reported-outcome/)
- [A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease](https://www.pedestalhealth.com/resources/publications/poster-presentation/a-prospective-assessment-of-the-impact-of-decompensation-of/)
- [Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort](https://www.pedestalhealth.com/resources/publications/poster-presentation/time-to-disease-progression-and-all-cause-mortality-in/)
- [Use of sodium-glucose transport protein 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with MASLD in a real-world setting is associated with lower all-cause mortality](https://www.pedestalhealth.com/resources/publications/poster-presentation/use-of-sodium-glucose-transport-protein-2-inhibitors-and/)
- [Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort](https://www.pedestalhealth.com/resources/publications/poster-presentation/characteristics-of-adult-mash-patients-and-factors/)
- [Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups](https://www.pedestalhealth.com/resources/publications/poster-presentation/understanding-metabolic-dysfunction-associated/)
- [Complication-Free Survival in a Real-World Cohort of PBC Patients: Deep Versus Adequate ALP Response to UDCA](https://www.pedestalhealth.com/resources/publications/poster-presentation/complication-free-survival-in-a-real-world-cohort-of-pbc/)
- [Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/concordance-of-masld-and-nafld-nomenclature-in-youth/)
- [High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/high-concordance-between-nonalcoholic-fatty-liver-disease/)
- [Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/relationship-between-liver-biopsy-fibrosis-stage-and/)
- [Non-invasive tests as a prediction tool to assess MASH resolution score](https://www.pedestalhealth.com/resources/publications/poster-presentation/non-invasive-tests-as-a-prediction-tool-to-assess-mash/)
- [A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/a-longitudinal-assessment-of-cardiovascular-risk-for-nash/)
- [Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting](https://www.pedestalhealth.com/resources/publications/poster-presentation/type-2-diabetes-increases-the-risk-of-progression-to/)
- [Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/real-world-use-of-glucagon-like-peptide-1-receptor-agonists/)
- [A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease](https://www.pedestalhealth.com/resources/publications/poster-presentation/a-prospective-assessment-of-disease-progression-impact-on/)
- [Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/validation-of-a-clinical-risk-based-classification-system/)
- [Impact of itch on quality of life in people with primary biliary cholangitis: a plain language summary](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/impact-of-itch-on-quality-of-life-in-people-with-primary/)
- [NASH Progression Rates Based on Fibrosis and Inflammation (NAS): A Paired Biopsy Analysis From a Natural History Cohort in the US](https://www.pedestalhealth.com/resources/publications/poster-presentation/nash-progression-rates-based-on-fibrosis-and-inflammation/)
- [Non-alcoholic Steatohepatitis Disease Progression in Participants from the United States TARGET-NASH Real World Longitudinal Observational Study](https://www.pedestalhealth.com/resources/publications/oral-presentation/non-alcoholic-steatohepatitis-disease-progression-in/)
- [A Prospective, Pragmatic Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients after Direct-Acting Antiviral (DAA) Therapy: DAA-PASS](https://www.pedestalhealth.com/resources/publications/poster-presentation/a-prospective-pragmatic-post-authorisation-safety-study-of/)
- [The Role of Disease Severity and Gender in Polypharmacy Among Patients with NAFLD Enrolled in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/the-role-of-disease-severity-and-gender-in-polypharmacy/)
- [Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/variation-in-alanine-aminotransferase-in-children-with-non/)
- [Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/impact-of-pruritus-on-quality-of-life-and-current-treatment/)
- [Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks](https://www.pedestalhealth.com/resources/publications/poster-presentation/longitudinal-alt-trajectories-are-generally-stable-among/)
- [The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)](https://www.pedestalhealth.com/resources/publications/oral-presentation/the-pervasive-impact-of-pruritus-on-quality-of-life-in/)
- [Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC (APASL)](https://www.pedestalhealth.com/resources/publications/oral-presentation/pruritus-in-primary-biliary-cholangitis-is-under-treated-in/)
- [Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/liver-biopsy-in-the-real-world-reporting-expert-concordance/)
- [Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/prevalence-and-factors-associated-with-statin-use-among/)
- [Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/patient-determinants-for-histologic-diagnosis-of-nafld-in/)
- [Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/weight-loss-and-weight-regain-in-usual-clinical-practice/)
- [Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study](https://www.pedestalhealth.com/resources/publications/poster-presentation/determination-of-optimal-thresholds-for-significant/)
- [Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/safety-and-effectiveness-of-tenofovir-alafenamide-in-usual/)
- [A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes](https://www.pedestalhealth.com/resources/publications/poster-presentation/a-pragmatic-clinical-prognostic-classification-suitable-for/)
- [Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice](https://www.pedestalhealth.com/resources/publications/poster-presentation/heterogeneous-documentation-and-poor-concordance-of-nash/)
- [Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study](https://www.pedestalhealth.com/resources/publications/poster-presentation/fibrosis-assessed-by-non-invasive-tests-is-similar-to-liver/)
- [The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC](https://www.pedestalhealth.com/resources/publications/poster-presentation/the-pervasive-impact-of-pruritus-on-quality-of--2020-aasld/)
- [Pruritus in Primary Biliary Cholangitis is Under-Treated in Clinical Practice: Results from TARGET-PBC](https://www.pedestalhealth.com/resources/publications/poster-presentation/pruritus-in-primary-biliary-cholangitis-is--2020-aasld/)
- [Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/opioid-use-is-more-common-in-non-alcoholic-fatty-liver/)
- [Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/lean-americans-with-nonalcoholic-fatty-liver-disease-have/)
- [A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/a-real-world-observational-cohort-of-patients-with/)
- [Weight Loss and Change in Alanine Aminotransferase (ALT) Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Receiving Standard Care in Real World Clinical Practice: TARGET-NASH](https://www.pedestalhealth.com/resources/publications/oral-presentation/weight-loss-and-change-in-alanine-aminotransferase-alt/)
- [Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus](https://www.pedestalhealth.com/resources/publications/oral-presentation/clinical-profile-of-nonalcoholic-fatty-liver-disease-in/)
- [Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/predicting-advanced-fibrosis-using-non-invasive-clinical/)
- [Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort](https://www.pedestalhealth.com/resources/publications/oral-presentation/incidence-of-achieving-weight-loss-goals-in-usual-clinical/)
- [Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort](https://www.pedestalhealth.com/resources/publications/poster-presentation/routinely-available-noninvasive-tests-perform-well-in/)
- [Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/patient-reported-outcomes-among-pediatric-patients-with/)
- [Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/patterns-of-medication-use-among-adult-patients-with/)
- [Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study (AASLD)](https://www.pedestalhealth.com/resources/publications/poster-presentation/effectiveness-of-tenofovir-alafenamide-in-patients-with/)
- [Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real-world cohort (DDW 2019)](https://www.pedestalhealth.com/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-autoimmune-hepatitis-aih/)
- [Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort (DDW 2019)](https://www.pedestalhealth.com/resources/publications/poster-presentation/change-in-lipids-characteristics-and-response-to/)
- [Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US](https://www.pedestalhealth.com/resources/publications/poster-presentation/regional-racial-ethnic-and-socioeconomic-disparities-and/)
- [The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease](https://www.pedestalhealth.com/resources/publications/poster-presentation/the-prescribing-patterns-and-use-of-statins-in-patients/)
- [Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity](https://www.pedestalhealth.com/resources/publications/poster-presentation/opioid-use-in-patients-with-nafld-prevalence-and/)
- [Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD](https://www.pedestalhealth.com/resources/publications/poster-presentation/lean-nafld-patients-have-lower-prevalence-of-cardiovascular/)
- [Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC)](https://www.pedestalhealth.com/resources/publications/poster-presentation/management-of-hepatocellular-carcinoma-hcc-in-a-real-life/)
- [Characterization of polypharmacy in patients with NAFLD](https://www.pedestalhealth.com/resources/publications/poster-presentation/characterization-of-polypharmacy-in-patients-with-nafld/)
- [Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC)](https://www.pedestalhealth.com/resources/publications/poster-presentation/patient-reported-indicators-of-health-and-symptoms-in-us/)
- [A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/a-real-world-observational-cohort-of-patients-with-primary/)
- [Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM)](https://www.pedestalhealth.com/resources/publications/poster-presentation/clinical-profile-of-adults-with-nonalcoholic/)
- [Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/nonalcoholic-fatty-liver-disease-in-children-in-the-u-s/)
- [Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)](https://www.pedestalhealth.com/resources/publications/poster-presentation/real-world-evidence-showing-high-rates-of-cardiovascular/)
- [Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC (DDW)](https://www.pedestalhealth.com/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-in-the-u-s-real-world/)
- [Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC (DDW)](https://www.pedestalhealth.com/resources/publications/poster-presentation/primary-biliary-cholangitis-pbc-in-the-u-s-clinical/)
- [Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study](https://www.pedestalhealth.com/resources/publications/abstract-manuscript/design-and-rationale-for-a-real-world-observational-cohort/)
- [Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH](https://www.pedestalhealth.com/resources/publications/poster-presentation/sustained-elevation-in-alkaline-phosphatase-is-associated/)
- [Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH (HEP DART)](https://www.pedestalhealth.com/resources/publications/poster-presentation/nonalcoholic-fatty-liver-disease-in-the-u-s-clinical/)

- [Pedestal Health (formerly Target RWE) at EASL 2025: Advancing HCC, MASH & PBC Research](https://www.pedestalhealth.com/resources/news/press-release/target-rwe-at-easl-2025-advancing-hcc-mash-pbc-research/)
- [An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data](https://www.pedestalhealth.com/resources/news/press-release/an-overview-of-mash-advancements-in-diagnosis-treatment-and-the-role-of-real-world-data/)
- [AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry)](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/aasld-opens-call-for-applications-for-sites-to-participate-in-target-ld-and-the-cirrhosis-quality-collaborative-cqc-data-registry/)
- [New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD](https://www.pedestalhealth.com/resources/news/press-release/new-patient-reported-outcome-insights-from-target-rwe-nash-check-reveals-stability-over-time-and-worse-scores-among-those-with-decompensated-cirrhosis-of-patients-with-masld/)
- [The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD](https://www.pedestalhealth.com/resources/news/press-release/the-liver-meeting-2024-research-cirrhosis-presentation-by-arun-j-sanyal-mbbs-md/)
- [The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD](https://www.pedestalhealth.com/resources/news/press-release/the-liver-meeting-2024-research-nash-check-presentation-by-arun-j-sanyal-mbbs-md/)
- [Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024](https://www.pedestalhealth.com/resources/news/press-release/target-rwe-highlights-glp-1-receptor-agonists-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-at-the-liver-meeting-2024/)
- [ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries](https://www.pedestalhealth.com/resources/news/press-release/acg-2024-target-rwe-presents-key-mash-and-egids-data-from-leading-liver-disease-gastroenterology-real-world-registries/)
- [New Target RWE Research Validates Updated Liver Disease Terminology in Children](https://www.pedestalhealth.com/resources/news/press-release/new-target-rwe-research-validates-updated-liver-disease-terminology-in-children/)
- [Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver Diseases](https://www.pedestalhealth.com/resources/news/partnership-announcement/target-rwe-unveils-latest-developments-in-target-liver-disease-and-cirrhosis-quality-collaborative-partnership-with-the-american-association-for-the-study-of-liver-diseases/)
- [Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions](https://www.pedestalhealth.com/resources/news/press-release/real-world-target-nash-analysis-shows-high-concordance-between-new-masld-definitions-and-prior-target-nash-pragmatic-definitions/)
- [GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024](https://www.pedestalhealth.com/resources/news/conference-presentation/glp-1-use-and-nash-check-patient-reported-outcomes-studies-from-target-rwe-presented-at-easl-2024/)
- [World's Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/world-s-largest-liver-disease-focused-registry-surpasses-400-000-patient-enrollment-milestone/)
- [Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/target-rwe-launches-novel-precision-medicine-platform-to-undertake-growing-unmet-medical-needs-in-liver-disease-gastroenterology-and-immune-mediated-inflammatory-conditions/)
- [TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options](https://www.pedestalhealth.com/resources/news/press-release/target-nash-offers-unprecedented-glimpse-into-growing-public-health-concerns-with-few-treatment-options/)
- [Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases](https://www.pedestalhealth.com/resources/news/partnership-announcement/target-rwe-releases-important-updates-on-the-cirrhosis-quality-collaborativetarget-liver-disease-partnership-with-the-american-association-for-the-study-of-liver-diseases/)
- [World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/world-leading-real-world-data-registry-target-nash-surpasses-7-000plus-enrolled-patients-and-500-000plus-months-of-patient-follow-up/)
- [Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023](https://www.pedestalhealth.com/resources/news/conference-presentation/event-recap-blog-target-nash-analysis-presented-at-ispor-2023-and-target-rwe-leaders-present-at-pmsa-2023/)
- [Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH](https://www.pedestalhealth.com/resources/news/press-release/validation-of-a-pragmatic-clinical-risk-based-classification-of-nash-new-supporting-real-world-evidence-from-target-nash/)
- [Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative](https://www.pedestalhealth.com/resources/news/partnership-announcement/target-rwe-and-the-american-association-for-the-study-of-liver-diseases-announce-research-agreement-for-cirrhosis-quality-collaborative/)
- [Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population](https://www.pedestalhealth.com/resources/news/press-release/real-world-data-finds-high-prevalence-of-pruritus-itching-and-fatigue-low-levels-of-treatment-in-primary-biliary-cholangitis-population/)
- [Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022](https://www.pedestalhealth.com/resources/news/conference-presentation/ilc2022-nonalcoholic-fatty-liver-disease-nafld-research-from-target-rwes-real-world-study-presented-at-international-liver-congress-2022/)
- [Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022](https://www.pedestalhealth.com/resources/news/conference-presentation/target-rwe-primary-biliary-cholangitis-pbc-encore-data-presented-at-apasl-2022/)
- [Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children](https://www.pedestalhealth.com/resources/news/press-release/large-real-world-study-uncovers-higher-prevalence-of-non-alcoholic-fatty-liver-disease-markers-liver-biopsy-and-cirrhosis-in-children/)
- [Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting](https://www.pedestalhealth.com/resources/news/publication-highlight/peer-reviewed-target-rwe-study-finds-wide-variance-in-nonalcoholic-steatohepatitis-nash-pathology-reporting/)
- [Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year's Meeting](https://www.pedestalhealth.com/resources/news/conference-presentation/update-from-paris-nash-2021-new-target-rwe-nonalcoholic-steatohepatitis-nash-data-presented-at-this-year-s-meeting/)
- [Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences](https://www.pedestalhealth.com/resources/news/press-release/target-rwe-hbv-research-on-antiviral-treatments-characteristics-and-clinical-outcomes-published-in-digestive-diseases-and-sciences/)
- [Liver International Publishes Hepatocellular Carcinoma RWE Review](https://www.pedestalhealth.com/resources/news/publication-highlight/liver-international-publishes-hepatocellular-carcinoma-rwe-review/)
- [TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease](https://www.pedestalhealth.com/resources/news/press-release/target-nash-study-finds-statins-underutilized-in-patients-with-nafld-and-at-risk-of-heart-disease/)
- [TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy](https://www.pedestalhealth.com/resources/news/press-release/target-nash-real-world-study-reveals-two-thirds-of-patients-with-nafld-had-no-record-of-liver-biopsy/)
- [Target RWE Shares Weight Loss Data From Ongoing NASH Study](https://www.pedestalhealth.com/resources/news/conference-presentation/target-rwe-shares-weight-loss-data-from-ongoing-nash-study/)
- [TARGET-HCC Initial Manuscript Published in Hepatology Communications](https://www.pedestalhealth.com/resources/news/publication-highlight/target-hcc-initial-manuscript-published-in-hepatology-communications/)
- [Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities](https://www.pedestalhealth.com/resources/news/conference-presentation/target-rwe-data-presented-at-aasld-virtual-meeting-provides-important-updates-for-nash-and-pbc-communities/)
- [TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use](https://www.pedestalhealth.com/resources/news/publication-highlight/target-nash-opioid-manuscript-press-release/)
- [Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study](https://www.pedestalhealth.com/resources/news/publication-highlight/target-nash-lean-manuscript-press-release/)
- [EASL 2020: TARGET-NASH Oral Presentation & Abstract Poster Recap](https://www.pedestalhealth.com/resources/news/conference-presentation/target-rwe-easl-2020/)
- [TARGET-NASH Expands to Europe, Enrolls First Participant](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/target-nash-europe-enrollment/)
- [TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/target-nash-observational-study-reaches-5-000-enrolled-patients/)
- [TARGET PharmaSolutions to advance NASH Research through new collaboration](https://www.pedestalhealth.com/resources/news/partnership-announcement/target-pharmasolutions-to-advance-nash-research-through-new-collaboration/)
- [TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences](https://www.pedestalhealth.com/resources/news/partnership-announcement/target-pharmasolutions-to-advance-research-in-nash-and-hepatitis-b-through-new-collaboration-with-gilead-sciences/)
- [TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B](https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/target-pharmasolutions-initiates-a-new-community-target-hbv-to-advance-the-understanding-of-hepatitis-b/)
- [Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research](https://www.pedestalhealth.com/resources/news/partnership-announcement/boehringer-ingelheim-partners-with-target-pharmasolutions-to-progress-nash-research/)
- [Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH](https://www.pedestalhealth.com/resources/news/partnership-announcement/intercept-icpt-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash/)
- [Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH](https://www.pedestalhealth.com/resources/news/partnership-announcement/bristol-myers-squibb-bmy-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash/)
- [Allergan Partners with TARGET PharmaSolutions to Advance NASH Research](https://www.pedestalhealth.com/resources/news/partnership-announcement/allergan-partners-with-target-pharmasolutions-to-advance-nash-research/)
- [Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual Meeting](https://www.pedestalhealth.com/resources/news/conference-presentation/intercept-announces-ocaliva-obeticholic-acid-data-in-pbc-to-be-presented-at-the-2016-aasld-annual-meeting/)

